Glucagon-Like Peptide-1 (GLP-1)-Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes
The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Glucagon‐like peptide‐1 (GLP‐1) is secreted by intestinal L‐cells following food intake, and plays an important role in glucose homeostasis due to its stimulation of glucose‐dependent insulin secretion. Further, GLP‐1 is also associated with protective effects on pancreatic β‐cells and the cardiovascular system, decreased appetite, and weight loss, making GLP‐1 derivatives an exciting treatment for type 2 diabetes and obesity. Despite these benefits, wild‐type GLP‐1 exhibits a short circulation time due to its poor metabolic stability and rapid renal clearance, and must be administered by injection, making it a poor therapeutic agent. Many strategies have been used to improve the circulation time of GLP‐1 (e.g., mutations, unnatural amino acids, depot formulations, use of exendin‐4 sequences, and fusions with high‐molecular‐weight proteins or polymers), with its therapeutic utility further improved by adding agonist activity for gastric inhibitory peptide and glucagon receptors. This minireview focuses on strategies that have been used to improve the pharmacokinetics of GLP‐1 and provides an overview of GLP‐1‐based therapeutics in the pipeline.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It enhances glucose-dependent insulin secretion from pancreatic β-cells [32], stimulates somatostatin secretion from δ-cells, which suppresses glucagon secretion from α-cells [31], and exerts cytoprotective effects on β-cells by inhibiting apoptosis, inducing proliferation, and supporting insulin biosynthesis [31,36]”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [36]
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Peptide therapeutics: current status and future directions
Fosgerau, K., & Hoffmann, T. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.003 · Cited by 3,030
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105
Biodegradation and biocompatibility of PLA and PLGA microspheres
Anderson, J. M., & Shive, M. S. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.004 · Cited by 814
Future directions for peptide therapeutics development
Kaspar, A. A., & Reichert, J. M. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.011 · Cited by 750
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
Research works printed but not linked: 9
- Krause A., 2010, Formulary, 45, 43
- Jackson S. H., 2010, Pharmacy Ther., 35, 498
- Willard F. S., 2012, Exp. Diabetes Res., 470851
- Woodward H. N., 2014, Patient Preference Adherence, 8, 789
- Pratley R. E., 2014, Diabetes Endocrinol., 2, 289
- Spiegelberg H., 1972, Clin. Exp. Immunol., 10, 599
- Jimenez-Solem E., 2010, Curr. Opin. Mol. Ther., 12, 790
- Davies M. L., 2016, Austin J. Endocrinol. Diabetes, 3, 1053
- 10.1021/bc049735 · doi:10.1021/bc049735
Cited by
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
Romero, F. A., Jones, C. T., Xu, Y., Fenaux, M., & Halcomb, R. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01701 · Cited by 120
Muscogiuri, G., Barrea, L., Faggiano, F., Maiorino, M. I., Parrillo, M., Pugliese, G., Ruggeri, R. M., Scarano, E., Savastano, S., Colao, A., et al. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01574-9 · Cited by 128
Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency
Alavi, S. E., Cabot, P. J., & Moyle, P. M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00308 · Cited by 95
Self-citationDissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
Paternoster, S., & Falasca, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00584 · Cited by 91
“Nonetheless, the pharmacological activation of the GLP-1R is clinically beneficial (179), offering an improved glycaemic control with lower cardiovascular morbidity and without the risk of hypoglycaemia associated with some current anti diabetic drugs (173).”
BackgroundRhea, E. M., Babin, A., Thomas, P., Omer, M., Weaver, R., Hansen, K., Banks, W. A., & Talbot, K. (2024) · Tissue Barriers · doi:10.1080/21688370.2023.2292461 · Cited by 81
Krajewski, P. K., Złotowska, A., & Szepietowski, J. C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216292 · Cited by 82
“7 of 14 They also display direct vasodilatory effects, which have been observed in individuals with obesity and type II diabetes [51].”
BackgroundInfluentialHuber, H., Schieren, A., Holst, J. J., & Simon, M.-C. (2024) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.01.007 · Cited by 62
“GLP-1 has been shown to positively affect several factors related to obesity and T2DM, including pancreatic β -cell function, blood glucose homeostasis, satiety, and food intake [6 – 9].”
BackgroundMu, X., Wang, R., Cheng, C., Ma, Y., Zhang, Y., & Lu, W. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2023.2217444 · Cited by 71
“Besides stimulating insulin secretion, GLP-1 can also protect pancreatic β cells and the cardiovascular system, reduce food intake, delay gastric emptying and weight loss, and has a significant role in slowing the development of diabetes (Cheang and Moyle 2018).”
Di Prospero, N. A., Yee, J., Frustaci, M. E., Samtani, M. N., Alba, M., & Fleck, P. (2021) · Clinical Obesity · doi:10.1111/cob.12433 · Cited by 60
“However, it is difficult to assess the relative contribution of the GLP-1 agonism compared to the GCGR agonism of JNJ-64565111 on weight loss without using the same molecule lacking the GCGR portion, as GLP-1 agonists are known to have markedly different activity based on structure, half-life and conjugation.(44) Addi…”
Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins
Tan, H., Su, W., Zhang, W., Wang, P., Sattler, M., & Zou, P. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190206105232 · Cited by 64
Zhao, T., Chen, H., Cheng, C., Zhang, J., Yan, Z., Kuang, J., Kong, F., Li, C., & Lu, Q. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109224 · Cited by 52
Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo
Frémaux, J., Venin, C., Mauran, L., Zimmer, R., Guichard, G., & Goudreau, S. R. (2019) · Nature Communications · doi:10.1038/s41467-019-08793-y · Cited by 60
Alavi, S. E., Cabot, P. J., Yap, G. Y., & Moyle, P. M. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00291 · Cited by 52
Self-citationStructural principles of insulin formulation and analog design: A century of innovation
Jarosinski, M. A., Dhayalan, B., Chen, Y., Chatterjee, D., Varas, N., & Weiss, M. A. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101325 · Cited by 58
Hedin, K. A., Zhang, H., Kruse, V., Rees, V. E., Bäckhed, F., Greiner, T. U., Vazquez-Uribe, R., & Sommer, M. O. A. (2023) · ACS Synthetic Biology · doi:10.1021/acssynbio.3c00455 · Cited by 44
Xu, J., Wei, G., Wang, J., Zhu, J., Yu, M., Zeng, X., Wang, H., Xie, W., & Kong, H. (2019) · Laboratory Investigation · doi:10.1038/s41374-018-0170-0 · Cited by 48
The signaling pathways in obesity‐related complications
Chandrasekaran, P., & Weiskirchen, R. (2024) · Journal of Cell Communication and Signaling · doi:10.1002/ccs3.12039 · Cited by 54
“145 In Liraglutide, structural modifications were made to GLP ‐ 1 to extend its half ‐ life to 13 h. 146 Similarly, in Semaglutide, Lys26 was attached to a hydrophobic C ‐ 18 fatty di ‐ acid moiety to inhibit glomerular filtration.”
BackgroundAlavi, S. E., Cabot, P. J., Raza, A., & Moyle, P. M. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00091 · Cited by 37
Self-citationStrategies for the delivery of antidiabetic drugs via intranasal route
Dholakia, J., Prabhakar, B. R., & Shende, P. K. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121068 · Cited by 38
Frémaux, J., Venin, C., Mauran, L., Zimmer, R., Koensgen, F., Rognan, D., Bitsi, S., Lucey, M., Jones, B. J., Tomás, A., et al. (2019) · Chemical Science · doi:10.1039/c9sc02079a · Cited by 35
Yadav, P., Khurana, A., Bhatti, J. S., Weiskirchen, R., & Navik, U. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106426 · Cited by 32
Guo, S., Yan, T., Shi, L., Liu, A., Zhang, T., Xu, Y., Jiang, W., Yang, Q., Yang, L., Liu, L., et al. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153507 · Cited by 34
Shen, J., Deng, X., Sun, R., Tavallaie, M. S., Wang, J., Cai, Q., Lam, C., Lei, S., Fu, L., & Jiang, F. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112850 · Cited by 32
Rameshrad, M., Razavi, B. M., Lalau, J., Broe, M. E. D., & Hosseinzadeh, H. (2020) · PubMed Central · doi:10.22038/ijbms.2020.41638.9832 · Cited by 41
“However, the half-life of active GLP-1 is very short, 2 min, due to enzymatic degradation especially by dipeptidyl peptidase (DPP)-4 (27).”
BackgroundLiang, L., Su, X., Guan, Y., Wu, B., Zhang, X., & Nian, X. (2024) · iScience · doi:10.1016/j.isci.2024.109784 · Cited by 34
Key milestones in the diabetes research: A comprehensive update
Gupta, A. K., Behl, T., & Sachdeva, M. (2020) · Obesity Medicine · doi:10.1016/j.obmed.2020.100183 · Cited by 32
Bai, X., Hao, J.-T., Zheng, R., Yan, C.-P., Wang, J., Yang, C., Zhang, W., & Zhao, Z. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07088-5 · Cited by 30
Singh, A. P., Guo, Y., Baldelli, A., & Singh, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092265 · Cited by 32
“Glucagon-like peptide 1 (GLP-1) has also been shown to be an effective drug for T2DM treatment [46,47].”
BackgroundNew Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals
Jarosinski, M. A., Chen, Y., Varas, N., Dhayalan, B., Chatterjee, D., & Weiss, M. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab849 · Cited by 26
“monitor -defined time-in-range metrics) and once-a-week ultra-basal analog formulations may enhance the efficacy of once-a-week GLP-1 agonists (88,89).”
BackgroundAbdulhameed, N., Babin, A., Hansen, K. M., Weaver, R. R., Banks, W. A., Talbot, K., & Rhea, E. M. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01537-1 · Cited by 27
“IRAs are forms of these hormones modified to prolong their otherwise very short half-lives in plasma (less than 2 min) [61].”
BackgroundResearch Progress on Dipeptidyl Peptidase Family: Structure, Function and Xenobiotic Metabolism
Qian, X., Zhang, J., Li, X., Song, P., & Zou, L. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210915103431 · Cited by 20
Vandemark, C., Nguyen, J., & Zhao, Z. (2023) · Molecules · doi:10.3390/molecules28031369 · Cited by 26
“and lixisenatide, liraglutide is the most stable against metabolic degradation by DPP4 with a half-life of 13 h following subcutaneous injection [17,18].”
BackgroundRuze, R., Xu, Q., Liu, G., Li, Y., Chen, W., Cheng, Z., Xiong, Y., Liu, S., Zhang, G., Hu, S., et al. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00126.2021 · Cited by 20
Pinto, S. F. T., Viegas, J. S. R., Cristelo, C., Pacheco, C., Barros, S., Buckley, S. T., Garousi, J., Gräslund, T., Santos, H. A., & Sarmento, B. F. C. C. (2024) · ACS Nano · doi:10.1021/acsnano.4c11172 · Cited by 22
New insights into nanomedicines for oral delivery of glucagon‐like peptide‐1 analogs
Pinto, S., Santos, H. A., & Sarmento, B. F. C. C. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1952 · Cited by 20
A free‐energy landscape for the glucagon‐like peptide 1 receptor GLP1R
Alhadeff, R., & Warshel, A. (2019) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25777 · Cited by 19
“GLP1R agonists (GLP1RAs), such as semaglutide and liraglutide, are increasingly used to treat diabetic patients,(32,33) exhibiting benefits such as reducing the risk of death from heart diseases in diabetic patients(32); having insulinotropic effects in type 1 diabetes patients(34); and are known to increase the growt…”
BackgroundBellanca, C. M., Augello, E., Benedetto, G. D., Burgaletto, C., Cantone, A. F., Cantarella, G., Bernardini, R., Polosa, R., & the DiaSmokeFree Working Group (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1406860 · Cited by 17
Peptide Multimerization as Leads for Therapeutic Development
Sheard, D. E., Li, W., O’brien-simpson, N. M., Separovic, F., & Wade, J. D. (2021) · Biologics · doi:10.3390/biologics2010002 · Cited by 17
Glucagon-Like peptide-1: A new therapeutic target to treat abdominal aortic aneurysm?
Raffort, J., Chinetti, G., & Lareyre, F. (2018) · Biochimie · doi:10.1016/j.biochi.2018.06.026 · Cited by 17
Weaver, E., Uddin, S., Cole, D. K., Hooker, A., & Lamprou, D. A. (2021) · Applied Sciences · doi:10.3390/app11094109 · Cited by 16
“The natural degradation time for GLP-1 post-administration is approximately 2 min [62] due to rapid degradation by the enzyme dipeptidyl peptidase 4.”
BackgroundLiu, W., Jin, R., Ma, F., Zhao, P., Su, Y., Wang, J., Zhang, Y., Wang, R., Zhu, J., & Liu, X. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141004 · Cited by 18
Prader–Willi Syndrome in Adults: An Update On Nutritional Treatment and Pharmacological Approach
Barrea, L., Vetrani, C., Fintini, D., de Alteriis, G., Panfili, F. M., Bocchini, S., Verde, L., Colao, A., Savastano, S., & Muscogiuri, G. (2022) · Current Obesity Reports · doi:10.1007/s13679-022-00478-w · Cited by 17
“Accordingly, GLP-1 receptor agonists may act determining a decrease in appetite and weight and stimulating the glucose-dependent insulin secretion with protective effects on pancreatic β-cells and cardiovascular system [99].”
BackgroundSani, E., Prato, G. D., Zenti, M. G., Bordugo, A., Trombetta, M., & Bonora, E. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220509225637 · Cited by 14
Karimifar, M., Afsar, J., Amini, M., Moeinzadeh, F., Feizi, A., & Aminorroaya, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-30643-7 · Cited by 15
Engineering PEG-fatty acid stapled, long-acting peptide agonists for G protein-coupled receptors
Lear, S., Amso, Z., & Shen, W. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.02.008 · Cited by 16
Lin, Q., Xia, X., Li, J., Zhou, Z. M., & Chen, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114672 · Cited by 14
Ohbatake, A., Yagi, K., Karashima, S., Shima, Y., Miyamoto, Y., Asaka, H., Okazaki, S., Kometani, M., Kawashiri, M., Takeda, Y., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0586-6 · Cited by 12
Effect of Semaglutide on High-Fat-Diet-Induced Liver Cancer in Obese Mice
Liu, Y., Chen, S., & Zhen, R. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00498 · Cited by 12
Veneti, S., & Τζιόμαλος, Κ. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i9.370 · Cited by 11
α/Sulfono-γ-AA peptide hybrids agonist of GLP-1R with prolonged action both in vitro and in vivo
Shi, Y., Lee, C., Sang, P., Amso, Z., Huang, D., Zhong, W., Gu, M., Wei, L., Nguyen-Tran, V. T. B., Zhang, J., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.10.014 · Cited by 9
Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review
Dias, D. D., Vasconcelos, A. R., Souza, A. C. R., Menezes, C. D., Silva, I. S. T. E., & Name, J. J. (2025) · Obesities · doi:10.3390/obesities5040088 · Cited by 8
A quinoxaline-based compound ameliorates bone loss in ovariectomized mice
Zhou, Y. J., Xue, X., Guo, Y., Liu, H., Hou, Z., Zhou, C., Wang, N., Li, F., & Wang, Y. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211032133 · Cited by 10
Oral glucagon-like peptide 1 analogue ameliorates glucose intolerance in db/db mice
Zhang, H., Dong, M., Yuan, S., & Jin, W. (2022) · Biotechnology Letters · doi:10.1007/s10529-022-03288-1 · Cited by 8
Physiology and pharmacology of glucagon-like peptide-1 receptor
Куркин, Д. В., Bakulin, D. A., Morkovin, E. I., Petrov, V. I., Strygin, A. V., Koryanova, K. N., Gorbunova, Y. V., Kolosov, Y. A., Ivanova, O. V., Pavlova, E. V., et al. (2024) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2023-11-4-347-380 · Cited by 13
Abbas, G., Haq, Q. M. I., Hamaed, A. M., Al-Sibani, M., & Hussain, H. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200131143231 · Cited by 6
Petsas, E., Kiouri, D. P., Georgiou, N., Siasos, G., Mavromoustakos, T., & Chasapis, C. T. (2025) · Molecules · doi:10.3390/molecules30214240 · Cited by 9
Hamza, A., & Șaramet, G. (2020) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2020.383 · Cited by 8
“Semaglutide Glucagon-like peptide 1 (GLP- 1) is an endogenous hormone produced by the L-cells from the intestines after food intake, first as proglucagon (20) which is proteolytically cleaved, in four different forms of GLP- 1 (21).”
BackgroundSustained release of GLP-1 analog from γ-PGA-PAE copolymers for management of type 2 diabetes
Zhang, L., Jin, M., Pan, Y., Yang, F., Wu, Y., Gao, J., Chen, T., Tan, S., Yang, T., Chen, Y., et al. (2023) · Biomaterials Advances · doi:10.1016/j.bioadv.2023.213352 · Cited by 5
Tătaru, I., Dragostin, O. M., Fulga, I., Boros, F., Carp, A., Maftei, A., Zamfir, C. L., & Nechita, A. (2022) · Expert Review of Medical Devices · doi:10.1080/17434440.2022.2113387 · Cited by 5
The Cascade System of Osmotic Homeostasis Regulation
Natochin, Y. V., Marina, A. S., & Ei, S. (2020) · Doklady Biological Sciences · doi:10.1134/s0012496620010056 · Cited by 4
Dhankhar, S., Mahajan, S., Chauhan, S., Saini, M., Garg, N., & Singh, T. G. (2024) · Current Bioactive Compounds · doi:10.2174/0115734072322250240924081053 · Cited by 4
Sun, M., Yin, P., Chen, S., & Wang, X. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00293 · Cited by 3
Hedin, K. A., Zhang, H., Kruse, V., Rees, V. E., Bäckhed, F., Greiner, T. U., Vazquez-Uribe, R., & Sommer, M. O. A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.21.521368 · Cited by 3
Rabbani, S. A., Saini, M., El-Tanani, M. E.-T., Kumar, R., Matalka, I. I., El‐Tanani, Y., Sharma, S., & Rizzo, M. (2026) · Pharmaceuticals · doi:10.3390/ph19050732 · Cited by 5
Glucose metabolism: Normal physiology, diabetic dysregulation, and therapeutic targets
Habtemariam, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-102922-0.00002-x · Cited by 2
Insulin Analogs and the Mode of Insulin Delivery: Recent Advances and Challenges
Bhagi, M., Kaur, J., Dhar, A., & Bhat, A. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010287216240324050651 · Cited by 4
GÓRSKA, A., & Arciszewski, M. B. (2020) · Medycyna Weterynaryjna · doi:10.21521/mw.6374 · Cited by 3
Kimura, S., Tsutsumi, S., Nakamura, N., Tsujihata, S., Fangjie, L., Nakashima, Y., Kita, S., Maenaka, K., Hashiya, F., Inagaki, M., et al. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100555 · Cited by 1
Nonalcoholic Fatty Liver Disease in the Post Liver Transplant Patient
Batisti, J., & Mehal, W. Z. (2020) · Current Transplantation Reports · doi:10.1007/s40472-020-00303-0 · Cited by 1
Noncardiovascular-derived therapeutic peptidomimetics in cardiovascular disease
Litmanovich, A., Ertracht, O., Blumberg, Y., Saad, M., Moady, G., & Qvit, N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820141-1.00013-3 · Cited by 2
Xu, Z., Liu, Z., Wang, Y., Xue, J., Chang, T., Cui, Y., Cheng, Y., Liu, G., Wang, W., Zhou, Y., et al. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2188192 · Cited by 1
Trends in Peptide Therapeutics
Brunel, F. M., Liu, F., & Mayer, J. P. (2019) · Wiley eBooks · doi:10.1002/9783527814695.ch1 · Cited by 2
Impact of the short - chain fatty acids on the microbiota - gut - brain axis
Solsona, R. M. (2021) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · Cited by 1
Progress in research of gastrointestinal motility regulation
Yu, H., Fu, M., Ji, X., & E-Ni, R.-G. (2020) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v28.i23.1183
Oral GLP-1 Analogue Ameliorates Obesity-Induced Diabetes In Db/Db MousePreprint
Zhang, H., Dong, M., & Jin, W. (2021) · Research Square · doi:10.21203/rs.3.rs-812353/v1
“Considering of lower half-life of wildtype GLP-1 for less than 2 min [17], GLP-1 analogues is been investigated to remedy their de ciency, such as restriction enzyme mutation, unnatural amino acid substitution, covalent complex and Exendin family from Glia monster [18].”
BackgroundXing, Y., Chen, J., Liu, J., Hou, X., Gao, Y., & Ma, H. (2024) · Research Square · doi:10.21203/rs.3.rs-3967086/v1
Xie, X., Kong, L., Lan, Z., Liu, X., Li, X., Cai, J., Meng, L., Yuan, G., Huang, C., Chen, Y., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5265213
Abdulhameed, N., Babin, A., Hansen, K., Weaver, R. R., Banks, W. A., Talbot, K., & Rhea, E. M. (2024) · Figshare · doi:10.6084/m9.figshare.26420326
Abdulhameed, N., Babin, A., Hansen, K., Weaver, R. R., Banks, W. A., Talbot, K., & Rhea, E. M. (2024) · Figshare · doi:10.6084/m9.figshare.26756596
Abdulhameed, N., Babin, A., Hansen, K., Weaver, R. R., Banks, W. A., Talbot, K., & Rhea, E. M. (2024) · Figshare · doi:10.6084/m9.figshare.26420552
Engineering core-shell polymer microgels to control the onset of glucose-regulated insulin release
Li, Y., Bhattacharya, K., Zhang, J., Roy, S., Roy, P. G., Shen, J., & Zhou, S. (2026) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2026.2722159
BindingDB (2021) · UC San Diego · doi:10.7270/q2dj5jxg
Metadata
- Authors
- Cheang, J. Y., & Moyle, P. M.
- Affiliations
- The University of Queensland (AU)
- Corresponding author
- Moyle, Peter M.
- ORCID
- Moyle, Peter M.
- Venue
- ChemMedChem
- Publisher
- Wiley
- Published
- 2018-02-28
- Volume
- 13
- Issue
- 7
- Pages
- 662-671
- ISSN
- 1860-7179 (ISSN-L)
- 1860-7187
- OpenAlex
- W2792698729
- Cited by
- 82
- References
- 73
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 16 · 2023: 9 · 2022: 9 · 2021: 14 · 2020: 13 · 2019: 11 · 2018: 2
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- ChemMedChem (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Queensland
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- glucagon-like peptide-1, GLP-1 receptor agonists, type 2 diabetes, obesity, pharmacokinetics, GLP-1 analogues, exendin-4, glucose-dependent insulinotropic polypeptide, glucagon receptor, pancreatic beta-cell protection, glucose homeostasis, insulin secretion
- MeSH terms
- Liraglutide, Exenatide, Animals, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Half-Life, Humans, Hypoglycemic Agents, Structure-Activity Relationship, Peptide Hormones, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.